After LT, 65% of the patients were treated with lamivudine (LMV), 9% adefovir dipivoxil (ADV), 12% entecavir (ETV), 28% tenofovir disoproxil fumarate (TDF). The majority of the patients (75%) were on tacrolimus based triple combination therapy (Tacrolimus+MMF+ Prednisone). HBV recurrence was occurred in 8 patients (2.7%).
HBV recurrent patients were older (p=0.005) and had longer post transplantation period (p= 0.031). Among them, 7 had HCC, 1 had HDV coinfection, and 2 had detectable serum HBVDNA levels prior to LT. Four patients were on LMV, 2 LMV+ADV, 1 ADV and 1 ETV. Overall, 44 patients died due to post-transplant complications or HCC recurrence and its progression. Two of them had HBV recurrence. The overall survival rate was 85%. No patients underwent re-transplantation because of HBV-induced graft failure. In conclusion, based on the result of the present study, a combination of NUC treatment Poziotinib in vivo and low dose HBIG is efficient in long-term prophylaxis of HBV recurrence after LT. Disclosures: The following people have nothing to disclose: Ramazan Idilman, Murat Akyildiz, Onur Keskin, Ali R788 cell line Tuzun, Tonguc U. Yilmaz, Necdet Guler, Onur
Yaprak, Gokhan Gungor, Yalcin Erdogan, Murat Dayangac, Deniz Balci, Kubilay Cinar, Acar Tuzuner, Selcuk Hazinedaroglu, Yaman Tokat, Sadik Ersoz, Abdulkadir Dokmeci Background and Aim The pegylated interferon plus ribavirin (PEG-IFN/R) therapy against hepatitis C virus (HCV) reinfection in living donor liver transplantation (LDLT) patients is difficult. Recently PEG-IFN/R plus protease inhibitor (teraprevir or sime-previr) therapy
Montelukast Sodium has been used and produced excellent results for non-transplanted patients with HCV. However there are limited data on treatment of HCV reinfection with PEG-IFN/R plus protease inhibitor in LDLT patients. Our aim of this study is to evaluate the prognosis-improving of patients who achieved Sustained viral response (SVR) by IFN therapy and present the possibility that PEG-IFN/R plus protease inhibitor therapy might contribute to prognosis-improving by their strong antiviral effects. Methods This study included eighty-six patients underwent HCV-related LDLT from Aug 2000 to Jan 2013 in Nagasaki university hospital. Thirty patients were treated with PEG-IFN/R therapy, four patients with PEG-IFN/R plus teraprevir therapy and eight with PEG-IFN/R plus simeprevir therapy. Other thirty-four patients didn’t receive IFN therapy. The prognosis of patients who had achieved SVR was compared with that of non-SVR to assess the prognosis-improving in the LDLT patients with SVR. Furthermore, the therapy effect of PEG-IFN/R with or without protease inhibitor was examined at 4 weeks and 12 weeks after treatment. Results Eight of thirty (26.6%) achieved SVR by PEG-IFN/R. Their mean duration of therapy for SVR was 747 days. Survival rate of patients who achieved SVR was higher than non-SVR significantly (p=0.